VanEck Video Gaming and eSports ETF vs Regeneron Pharmaceuticals Inc — how do they compare? VanEck Video Gaming and eSports ETF trades at $99.66 (market cap $248.06M), while Regeneron Pharmaceuticals Inc trades at $750.8 (market cap $76.14B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 306.9× VanEck Video Gaming and eSports ETF's market cap, and Regeneron Pharmaceuticals Inc pays a 0.51% dividend while VanEck Video Gaming and eSports ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold VanEck Video Gaming and eSports ETF for 65 Days and Regeneron Pharmaceuticals Inc for 107 Days on average.
| ESPO | REGN | |
|---|---|---|
Market Cap | $248.06M | $76.14B |
Volume | 13,622 | 500,239 |
Sector | Sector/Thematic | Health |
52-Week High | $118.68 | $852.03 |
52-Week Low | $85.25 | $557.73 |
Typical Hold Time | 65 Days | 107 Days |
Enterprise Value | — | $70.85B |
Dividend Yield | — | 0.51% |
Signals from Pluang's Aura AI — not financial advice
ESPO trades at $97.32, down 0.33% on the day, with a bullish technical signal from moving averages and neutral oscillators. Key support is at $97 and resistance at $98. Financial ratios are unavailable in the provided data, limiting fundamental insight. No recent news is available to drive sentiment.
The outlook is mixed: technicals suggest upward momentum, but the absence of fundamental data and recent news creates uncertainty. Risks include market volatility and lack of visibility on financial health. Investors need updated earnings and guidance for a clearer investment case.
Regeneron Pharmaceuticals (REGN) trades at $739.28, down 0.38% on the day, with a bearish technical signal and neutral oscillators. The company shows strong fundamentals with a P/E of 18.3, net income margin of 27.86%, and consistent earnings beats in recent quarters. Recent news highlights a major $8 billion immunology alliance expansion with Sanofi, including a $1 billion upfront payment, reinforcing its pipeline strength and long-term growth prospects.
The outlook remains positive driven by robust profitability, strategic collaborations, and a bullish analyst consensus with a $849.84 price target. Key risks include competitive pressures in key drug markets and reliance on successful clinical trial outcomes. Institutional sentiment is strong with no sell ratings, supporting a favorable risk-reward profile for investors seeking exposure to biopharmaceutical innovation.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
ESPO is a thematic ETF that invests in the global video gaming and eSports industry. It provides exposure to companies involved in game development, hardware, and streaming, including major firms like Tencent, Nintendo, and Electronic Arts.
Read more on ESPO →Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →